Semaglutide vs. Tirzepatide: Which GLP-1 Is Right For You?
Two of the most powerful weight loss medications available today work differently — here's how to know which one fits your body, goals, and history.
Semaglutide and tirzepatide have transformed modern weight management. Both are injectable medications, both quiet appetite signals, and both can produce dramatic, sustained weight loss when paired with the right clinical support — but they are not interchangeable.
How they work
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating, slowing gastric emptying and signaling satiety to the brain. Tirzepatide is a dual GIP/GLP-1 agonist — it activates a second metabolic pathway alongside GLP-1, which appears to amplify both appetite suppression and metabolic efficiency.
What the clinical data shows
In the STEP trials, semaglutide produced an average weight loss of roughly 15% of body weight over 68 weeks. In SURMOUNT-1, tirzepatide pushed that average to 20.9% at the highest dose. Real-world results vary, but the trend is clear: tirzepatide tends to produce greater absolute weight loss for most patients.
Side effect profiles
Both medications share a common side effect family — nausea, constipation, occasional fatigue during dose escalation. Tirzepatide's dual action can produce slightly more pronounced GI effects in the first few weeks, but most patients adapt within a month.
Which one is right for you?
If you have a history of GI sensitivity, a slower titration with semaglutide may be the smoother path. If you have a higher BMI, insulin resistance, or have plateaued on semaglutide, tirzepatide may unlock further progress. Your Valora physician will review your labs, medical history, and goals to match the molecule to you — not the other way around.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.— New England Journal of Medicine, 2021.
- 2.Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.— New England Journal of Medicine, 2022.
- 3.Wegovy (semaglutide) Prescribing Information.— U.S. Food and Drug Administration, 2024.
- 4.Zepbound (tirzepatide) Prescribing Information.— U.S. Food and Drug Administration, 2023.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
